XBiotech Announces Addition Of Vice President Of Clinical Operations

AUSTIN, Texas, June 23, 2014 /PRNewswire/ -- XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's clinical trial team and manage the Company's international clinical operations.

Mr. Gonzales joins XBiotech from INC Research where he managed large, global pivotal phase III trials. Mr. Gonzales has B.S. & M.S. degrees in chemistry and biology and also holds a M.B.A. Mr. Gonzales comes to XBiotech with 20 years of industry experience with clinical operations and program management expertise and directly contributed to all stages of development for Lemtrada (alemtuzumab), a therapeutic monoclonal antibody.

Mr. Gonzales stated, "It is an exciting time to be working with monoclonal antibodies and XBiotech is on the cutting edge with its True Human molecule (Xilonix). The Company is strategically positioned to make great strides in offering a treatment option for patients with colorectal cancer. I am thrilled to join the XBiotech team and look forward to applying my experience regarding monoclonal antibody development to usher Xilonix to regulatory approval."

John Simard, the Company's Chairman & CEO stated, "Mr. Gonzales is seasoned in all stages of drug development, from pre-clinical activities through market registration. We are delighted to have him join the team at this exciting juncture, including launch of our European Phase III registration program."

ABOUT XBIOTECH

XBiotech is leading the commercialization of biological therapiesincluding the discovery and development of True Human antibodies. The Company's lead product candidatein Phase III clinical studiesis a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and reduce lead times for biological drugs, ushering in a new era for cost and development efficiency in the biopharmaceutical industry.

Contact:
Ashley Otero
XBiotech
[email protected]
512.386.2930

SOURCE XBiotech

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.